Clinical Trial Update: Study to Test the Effect of CDP870 in the Treatment of Crohn's Disease Over 26 Weeks, Comparing CDP870 to a Dummy Drug (Placebo), Following 3 Doses of Active Drug (CDP870). [Phase 3]

View source ↗

Summary

Phase 3 study assessing CDP870 (certolizumab pegol) in Crohn's disease over 26 weeks, comparing to placebo. The trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• CDP870 (certolizumab pegol)

Snippet

Sponsor: UCB Pharma | Conditions: Crohn's Disease | Phase 3 | Status: COMPLETED